. 2020 Dec;8(24):1711. doi: 10.21037/atm-20-1060

Table 3. Incidence of ovarian cancer in metformin users among women with type 2 diabetes.

Authors, year	Design	Region and period	Patients	Reference group	Main results
Bodmer et al. 2011 (52)	Register-based case-control	UK 1995−2009	1,611 ovarian cancers of which 85 were in women with T2D and 41 in metformin users	Women with T2D and no prior metformin use	OR 0.38 (95% CI: 0.18−0.81) when ≥10 prescriptions of metformin
Bodmer et al. 2011 (52)	Register-based case-control	UK 1995−2009		Women with T2D and no prior metformin use	OR 0.59 (95% CI: 0.25−1.41) when <10 prescriptions of metformin
Tseng 2015 (53)	Register-based cohort	Taiwan 1998−2009	Cohort size 479,475 with 3,201 ovarian cancers of which 601 were in metformin users	Women with T2D and no use of metformin	aHR 0.66 (95% CI: 0.59−0.73)
Urpilainen et al. 2018 (54)	Register-based cohort and case-control	Finland 1996−2011	Cohort size 137,643 with 303 ovarian cancer cases	Women with T2D using other oral ADM	Full cohort aHR 1.02 (95% CI 0.72−1.45)
Urpilainen et al. 2018 (54)	Register-based cohort and case-control	Finland 1996−2011	Cohort size 137,643 with 303 ovarian cancer cases	Women with T2D using other oral ADM	Case-control aHR 0.91 (95% CI: 0.61−1.34)

T2D, type 2 diabetes; ADM, antidiabetic medication; OR, odds ratio; CI, confidence interval; aHR, adjusted hazard ratio.